AMENDMENTS TO THE CLAIMS

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1-14. (Canceled)

15. (Currently amended) A method for preventing or alleviating infection by an Epstein-Barr virus comprising

vaccinating or administering to an individual

an extracellular component of the Epstein-Barr virus expressed during latency in a pharmaceutically acceptable carrier for administration of the virus or viral component in an amount and mode of administration effective to alleviate or prevent-the infection.

- 16. (Original) The method of claim 15 wherein the component of the Epstein-Barr virus is selected from the group consisting of LMP-1, LMP-2A, LMP-2B, LP peptides presented in HLA, and EBNA peptides presented in HLA.
- 17. (Original) The method of claim 15 wherein the component of the Epstein-Barr virus is LMP-2A or LMP-2B.
 - 18. (Canceled)
- 19. (Currently amended) The method of claim 15 wherewherein the component of the Epstein-Barr virus is expressed in the plasma membrane of a host cell.
- 20. (Original) The method of claim 15 wherein the individual has symptoms of or is at risk of developing an autoimmune disorder selected from the group consisting of systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, juvenile onset diabetes mellitus, Wegener's granulomatosis inflammatory bowel disease, polymyositis, dermatomyositis, multiple

endocrine failure, Schmidt's syndrome, autoimmune uveitis, Addison's disease, adrenalitis, primary biliary cirrhosis, Graves' disease, thyroiditis, Hashimoto's thyroiditis, autoimmune thyroid disease, pernicious anemia, lupoid hepatitis, demyelating diseases, multiple sclerosis, subacute cutaneous lupus erythematosus, hypoparathyroidism, Dressler's syndrome, myasthenia gravis, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, autoimmune hemolytic anemia, pemhigus vulgaris, pemphigus, bullous pemphigoid, dermatitis herpetiformis, alopecia areata, autoimmune cystitis, pemphigoid, scleroderma, progressive systemic sclerosis, CREST syndrome (calcinosis, Raynaud's esophageal dysmotility, sclerodactyly, and telangiectasia), adult onset diabetes mellitus (Type II diabetes), male or female autoimmune infertility, ankylosing spondylitis, ulcerative colitis, Crohn's disease, mixed connective tissue disease, polyarteritis nodosa, systemic necrotizing vasculitis, juenile onset rheumatoid arthritis, glomerulonephritis, atopic dermatitis, atopic rhinitis, Goodpasture's syndrome, Chagas' disease, sarcoidosis, rheumatic fever, asthma, recurrent abortion, antiphospholipid syndrome, farmer's lung, erythema multiform, postcardotomy syndrome, Cushing's syndrome, autoimmune chronic active hepatitis, bird-fancier's lung, allergic encephalomyelitis, toxic necrodermal lysis, alopecia, Alport's syndrome, alveolitis, allergic alveolitis, fibrosing alveolitis, interstitial lung disease, erythema nodosum, pyoderma gangrenosum, transfusion reaction, chronic fatigue syndrome, fibromyalgia, Takayasu's arteritis, Kawasaki's disease, polymyalgia rheumatica, temporal arteritis, giant cell arteritis, Sampter's syndrome (triaditis also called, nasal polyps, eosinophilia, and asthma), Behcet's disease, Caplan's syndrome, dengue, encephalomvositis, endocarditis, myocarditis, endomyocardial fibrosis, endophthalmitis, erythema elevatum et diutinum, psoriasis, erythroblastosis fetalis, fascitis with eosinophilia, Shulman's syndrome, Felty's syndrome, filariasis, cyclitis, chronic cyclitis, heterochromic cyclitis, Fuch's cyclitis, IgA nephropathy, Henoch-Schonlein purpura, glomerulonephritis, cardiomyopathy, post vaccination syndromes, Hodgkin's and non-Hodgkin's lymphoma, renal cell carcionoma, Eaton-Lambert syndrome, relapsing polychondritis, thrombotic thrombocytopenic purpura.

21. (Currently amended) The method of claim 15 wherein the vaceine component is administered prior to infection with Epstein-Barr virus.

- administered to an individual who has or has previously had an infection with Epstein-Barr virus.
 - 23. (Original) The method of claim 20 wherein the autoimmune disorder is systemic lupus erythematosus.
 - 24. (Original) The method of claim 20 wherein the autoimmune disease is Sjogren's syndrome.
 - 25. (Original) The method of claim 20 wherein the autoimmune disorder is mixed connective tissue disease.
 - 26. (Original) The method of claim 20 wherein the autoimmune disorder is rheumatoid arthritis.
 - 27. (Original) The method of claim 20 wherein the autoimmune disorder is Hodgkins' disease.
 - 28. (Original) The method of claim 20 wherein the autoimmune disorder is nasopharyngeal carcinoma.
 - 29. (Original) The method of claim 20 wherein the autoimmune disorder is multiple myeloma.
 - 30. (Original) The method of claim 20 wherein the autoimmune disorder is lymphoma of a category associated with EBV infection.
 - 31. (Currently amended) The method of claim 15 wherein the hostindividual is infected with the human immunodeficiency virus.

(Currently amended) The method of claim 15 wherein the hostindividual has an 32. immunodeficiency.

33-44. (Canceled)